Eledon Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Eledon Pharmaceuticals, Inc. (ELDN) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $2.08 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2023-03-30
- Eledon Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2022-12-31 was $210.00K, a 28.83% increase year-over-year.
- Eledon Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2022-09-30 was $2.91M, a 112.47% increase year-over-year.
- Eledon Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2022-06-30 was $359.00K.
- Eledon Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2022-03-31 was -$1.40M, a 163.11% decline year-over-year.
- Eledon Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $2.08M, a 2.89% decline from fiscal 2021.
- Eledon Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2021 was $2.14M.
- Eledon Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2020 was -$39.00K.
- Eledon Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2019 was -$1.39M, a 227.24% decline from fiscal 2018.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2022-12-31 | $210.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $3.12M derived: sum of 2 quarters · filed 2023-03-30 | $3.48M derived: sum of 3 quarters · filed 2023-03-30 | $2.08M 10-K · filed 2023-03-30 |
| 2022-09-30 | $2.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $3.27M derived: sum of 2 quarters · filed 2022-11-14 | $1.87M 10-Q · filed 2022-11-14 | $2.03M derived: sum of 4 quarters · filed 2023-03-30 |
| 2022-06-30 | $359.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$1.04M 10-Q · filed 2022-08-11 | -$879.00K derived: sum of 3 quarters · filed 2023-03-30 | $492.00K derived: sum of 4 quarters · filed 2023-03-30 |
| 2022-03-31 | -$1.40M 10-Q · filed 2022-05-12 | -$1.24M derived: sum of 2 quarters · filed 2023-03-30 | $133.00K derived: sum of 3 quarters · filed 2023-03-30 | -$1.48M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-12-31 | $163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $1.53M derived: sum of 2 quarters · filed 2023-03-30 | -$77.00K derived: sum of 3 quarters · filed 2023-03-30 | $2.14M 10-K · filed 2023-03-30 |
| 2021-09-30 | $1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$240.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.98M 10-Q · filed 2022-11-14 | -$2.07M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $609.00K 10-Q · filed 2022-08-11 | -$3.44M derived: sum of 3 quarters · filed 2022-08-11 | $803.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $2.22M 10-Q · filed 2022-05-12 | -$1.83M derived: sum of 2 quarters · filed 2022-05-12 | $2.41M derived: sum of 3 quarters · filed 2022-05-12 | $1.63M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $194.00K derived: sum of 2 quarters · filed 2022-03-24 | -$591.00K derived: sum of 3 quarters · filed 2022-03-24 | -$39.00K 10-K · filed 2022-03-24 |
| 2020-09-30 | $4.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $3.46M derived: sum of 2 quarters · filed 2021-11-12 | $4.01M 10-Q · filed 2021-11-12 | $3.67M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$785.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$233.00K 10-Q · filed 2021-08-12 | -$575.00K derived: sum of 3 quarters · filed 2021-08-12 | -$866.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $552.00K 10-Q · filed 2021-05-14 | $210.00K derived: sum of 2 quarters · filed 2021-05-14 | -$81.00K derived: sum of 3 quarters · filed 2021-05-14 | -$1.38M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | -$342.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$633.00K derived: sum of 2 quarters · filed 2021-03-31 | -$1.93M derived: sum of 3 quarters · filed 2021-03-31 | -$1.39M 10-K · filed 2021-03-31 |
| 2019-09-30 | -$291.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | -$1.59M derived: sum of 2 quarters · filed 2020-11-16 | -$1.05M 10-Q · filed 2020-11-16 | -$119.00K derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | -$1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$759.00K 10-Q · filed 2020-08-14 | $172.00K derived: sum of 3 quarters · filed 2020-08-14 | $323.00K derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | $537.00K 10-Q · filed 2020-05-15 | $1.47M derived: sum of 2 quarters · filed 2020-05-15 | $1.62M derived: sum of 3 quarters · filed 2020-05-15 | $1.45M derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $931.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-17 | $1.08M derived: sum of 2 quarters · filed 2020-03-17 | $915.00K derived: sum of 3 quarters · filed 2020-03-17 | $1.09M 10-K · filed 2020-03-17 |
| 2018-09-30 | $151.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | -$16.00K derived: sum of 2 quarters · filed 2019-11-13 | $163.00K 10-Q · filed 2019-11-13 | -$797.00K derived: sum of 4 quarters · filed 2019-11-13 |
| 2018-06-30 | -$167.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $12.00K 10-Q · filed 2019-08-13 | -$948.00K derived: sum of 3 quarters · filed 2019-08-13 | -$1.95M derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-03-31 | $179.00K 10-Q · filed 2019-05-14 | -$781.00K derived: sum of 2 quarters · filed 2019-05-14 | -$1.79M derived: sum of 3 quarters · filed 2019-05-14 | -$2.15M derived: sum of 4 quarters · filed 2019-05-14 |
| 2017-12-31 | -$960.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | -$1.97M derived: sum of 2 quarters · filed 2019-03-28 | -$2.33M derived: sum of 3 quarters · filed 2019-03-28 | -$1.96M 10-K · filed 2019-03-28 |
| 2017-09-30 | -$1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$1.37M derived: sum of 2 quarters · filed 2018-11-13 | -$998.00K 10-Q · filed 2018-11-13 | -$845.00K derived: sum of 4 quarters · filed 2018-11-13 |
| 2017-06-30 | -$368.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $7.00K 10-Q · filed 2018-08-07 | $160.00K derived: sum of 3 quarters · filed 2018-08-07 | $149.00K derived: sum of 4 quarters · filed 2018-08-07 |
| 2017-03-31 | $375.00K 10-Q · filed 2018-05-11 | $528.00K derived: sum of 2 quarters · filed 2018-05-11 | $517.00K derived: sum of 3 quarters · filed 2018-05-11 | |
| 2016-12-31 | $153.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $142.00K derived: sum of 2 quarters · filed 2018-04-02 | -$65.00K 10-K · filed 2018-04-02 | |
| 2016-09-30 | -$11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$218.00K 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | -$207.00K 10-Q · filed 2017-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |